Conference Reports

Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Orlando, Florida
16 February 2017 - 18 February 2017
Amsterdam
27 January 2017 - 30 January 2017
Singapore
16 December 2016 - 19 December 2016
San Diego, California
03 December 2016 - 06 December 2016
San Antonio, Texas
06 December 2016 - 10 December 2016
Vienna
04 December 2016 - 07 December 2016
Copenhagen
07 October 2016 - 11 October 2016
Singapore
20 July 2016 - 24 July 2016
Chiang Mai
13 May 2016 - 15 May 2016
Geneva
13 April 2016 - 16 April 2016
San Francisco, CA
07 January 2016 - 09 January 2016
San Antonio, Texas, US
08 December 2015 - 12 December 2015
Orlando, Florida, US
05 December 2015 - 08 December 2015
San Antonio, TX
18 October 2015 - 21 October 2015
Vienna
25 September 2015 - 29 September 2015
Philadelphia, PA
18 April 2015 - 22 April 2015
Geneva
15 April 2015 - 18 April 2015
San Antonio, TX
09 December 2014 - 13 December 2014
San Francisco, CA
06 December 2014 - 09 December 2014
21 November 2014 - 22 November 2014
Chicago, Illinois
30 May 2014 - 03 June 2014
Tel Aviv
18 June 2014 - 19 June 2014
Geneva
26 March 2014 - 29 March 2014
San Antonio
10 December 2013 - 14 December 2013
New Orleans, Louisiana
07 December 2013 - 10 December 2013
Amsterdam
27 September 2013 - 01 October 2013
Chicago, Illinois
31 May 2013 - 04 June 2013
Washington D.C
06 April 2013 - 10 April 2013
08 November 2012 - 09 November 2012
San Antonio Texas
04 December 2012 - 08 December 2012
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jenny Ng, 2 years ago

First results from the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) shows no benefit of adding lapatinib to standard trastuzumab adjuvant therapy in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Jairia Dela Cruz, one year ago
Neither a specific diagnostic approach nor “a gender-driven” therapy is currently available for women with lung cancer, according to an expert who discussed existing assumptions and evidence at the recent Asia Pacific Lung Cancer Conference 2016.
Kavitha G. Shekar, one year ago

Erdosteine protects lung cancer patients against cisplatin-induced nephrotoxicity, say researchers at the recent IASLC Asia Pacific Lung Cancer Conference (APLCC) 2016 in Chiang Mai, Thailand.